A detailed history of Meiji Yasuda Life Insurance CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Meiji Yasuda Life Insurance CO holds 28,833 shares of VRTX stock, worth $14.5 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares
28,833
Previous 10,582 172.47%
Holding current value
$14.5 Million
Previous $4.42 Million 205.54%
% of portfolio
0.27%
Previous 0.09%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$392.81 - $485.53 $7.17 Million - $8.86 Million
18,251 Added 172.47%
28,833 $13.5 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $306,175 - $335,006
751 Added 7.64%
10,582 $4.42 Million
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $817,712 - $979,061
2,384 Added 32.01%
9,831 $4 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $483,935 - $518,680
1,431 Added 23.79%
7,447 $2.59 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $138,344 - $154,840
-440 Reduced 6.82%
6,016 $2.12 Million
Q1 2023

May 10, 2023

SELL
$283.23 - $323.1 $722,802 - $824,551
-2,552 Reduced 28.33%
6,456 $2.03 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $299,762 - $337,232
1,049 Added 13.18%
9,008 $2.6 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $454,557 - $507,179
1,660 Added 26.35%
7,959 $2.3 Million
Q2 2022

Aug 16, 2022

SELL
$234.96 - $292.55 $52,396 - $65,238
-223 Reduced 3.42%
6,299 $1.78 Million
Q1 2022

May 17, 2022

SELL
$221.42 - $260.97 $233,155 - $274,801
-1,053 Reduced 13.9%
6,522 $1.7 Million
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $27,082 - $34,187
153 Added 2.06%
7,575 $1.66 Million
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $186,831 - $209,079
1,030 Added 16.11%
7,422 $1.35 Million
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $26,436 - $31,175
-141 Reduced 2.16%
6,392 $1.29 Million
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $16,561 - $19,304
-80 Reduced 1.21%
6,533 $1.4 Million
Q4 2020

Feb 12, 2021

SELL
$207.01 - $276.09 $270,769 - $361,125
-1,308 Reduced 16.51%
6,613 $1.56 Million
Q3 2020

Nov 12, 2020

BUY
$255.65 - $303.1 $178,955 - $212,170
700 Added 9.69%
7,921 $2.16 Million
Q2 2020

Aug 13, 2020

BUY
$225.48 - $295.8 $196,393 - $257,641
871 Added 13.72%
7,221 $2.1 Million
Q1 2020

May 14, 2020

BUY
$199.77 - $247.81 $290,265 - $360,067
1,453 Added 29.67%
6,350 $1.51 Million
Q4 2019

Feb 14, 2020

SELL
$166.71 - $223.91 $285,407 - $383,333
-1,712 Reduced 25.9%
4,897 $1.07 Million
Q3 2019

Nov 13, 2019

BUY
$166.23 - $187.09 $309,187 - $347,987
1,860 Added 39.17%
6,609 $1.12 Million
Q2 2019

Aug 14, 2019

SELL
$164.61 - $190.37 $75,885 - $87,760
-461 Reduced 8.85%
4,749 $871,000
Q1 2019

May 14, 2019

BUY
$163.73 - $194.7 $501,177 - $595,976
3,061 Added 142.44%
5,210 $958,000
Q4 2018

Feb 12, 2019

SELL
$151.91 - $192.21 $35,091 - $44,400
-231 Reduced 9.71%
2,149 $356,000
Q3 2018

Nov 13, 2018

BUY
$167.73 - $192.74 $191,212 - $219,723
1,140 Added 91.94%
2,380 $459,000
Q2 2018

Aug 13, 2018

SELL
$145.72 - $169.96 $255,010 - $297,430
-1,750 Reduced 58.53%
1,240 $211,000
Q1 2018

May 14, 2018

BUY
$151.6 - $177.13 $453,284 - $529,618
2,990 New
2,990 $487,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Meiji Yasuda Life Insurance CO Portfolio

Follow Meiji Yasuda Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meiji Yasuda Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Meiji Yasuda Life Insurance CO with notifications on news.